Evidence map›Paper›PMID 36293475›Full record

ArticleInternational journal of molecular sciences2022

Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.

Natalia V Chebotareva, Anatoliy Vinogradov, Alexander G Brzhozovskiy, Daria N Kashirina, Maria I Indeykina, Anna E Bugrova, Marina Lebedeva, Sergey Moiseev, Evgeny N Nikolaev, Alexey S Kononikhin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Natalia V ChebotarevaNephrology Department, Sechenov First Moscow State Medical University, Trubezkaya, 8, 119048 Moscow, Russia.
Anatoliy VinogradovDepartment of Internal Medicine, Lomonosov Moscow State University, GSP-1, Leninskie Gory, 119991 Moscow, Russia.
Alexander G BrzhozovskiyInstitute of Biomedical Problems-Russian Federation State Scientific Research Center, Russian Academy of Sciences, Khoroshevskoe Shosse, 76A, 123007 Moscow, Russia.
Daria N KashirinaInstitute of Biomedical Problems-Russian Federation State Scientific Research Center, Russian Academy of Sciences, Khoroshevskoe Shosse, 76A, 123007 Moscow, Russia.ORCID 0000-0002-9646-7275
Maria I IndeykinaSkolkovo Institute of Science and Technology, Bolshoy Boulevard 30, Bld. 1, 121205 Moscow, Russia.ORCID 0000-0002-8177-7449
Anna E BugrovaSkolkovo Institute of Science and Technology, Bolshoy Boulevard 30, Bld. 1, 121205 Moscow, Russia.ORCID 0000-0003-1515-9447
Marina LebedevaNephrology Department, Sechenov First Moscow State Medical University, Trubezkaya, 8, 119048 Moscow, Russia.ORCID 0000-0002-5923-1837
Sergey MoiseevNephrology Department, Sechenov First Moscow State Medical University, Trubezkaya, 8, 119048 Moscow, Russia.
Evgeny N NikolaevSkolkovo Institute of Science and Technology, Bolshoy Boulevard 30, Bld. 1, 121205 Moscow, Russia.
Alexey S KononikhinSkolkovo Institute of Science and Technology, Bolshoy Boulevard 30, Bld. 1, 121205 Moscow, Russia.ORCID 0000-0002-2238-3458
Skolkovo Institute of Science and Technology · RUSechenov University · RULomonosov Moscow State University · RU

Funding

Russian Science Foundation 21-74-20173
6 · The paper itself

Abstract

Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary podocyte damage that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of these diseases is ongoing. Our aim was to determine of the proteomic profile of urine from patients with FSGS and MCD. Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study. For a comprehensive assessment of the severity of FSGS a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second score-depending on the proteinuria level, the third score-resistance to steroid therapy. Patients with the sum of these scores of less than 3 were included in group 1, with 3 or more-in group 2. The urinary proteome was analyzed using liquid chromatography/mass spectrometry. The proteome profiles of patients with severe progressive FSGS from group 2, mild FSGS from group 1 and MCD were compared. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Patients from the FSGS group 2 showed a significantly different profile from both FSGS group 1 and MCD. Among the 47 significantly differentiating proteins, the most significant were apolipoprotein A-IV, hemopexin, vitronectin, gelsolin, components of the complement system (C4b, factors B and I), retinol- and vitamin D-binding proteins. Patients with mild form of FSGS and MCD showed lower levels of Cystatin C, gelsolin and complement factor I.

Indexed as

Glomerulosclerosis, Focal SegmentalNephrosis, LipoidBiomarkersComplement Factor ICystatin CGelsolinHemopexinHumansProteomeProteomicsSteroidsVitamin AVitamin DVitronectinBiomarkersComplement Factor ICystatin CGelsolinHemopexinProteomeSteroidsVitamin AVitamin DVitronectinFSGSmass spectrometryMCDpodocyte dysfunctionurine proteome

Identifiers

PMID36293475
PMCPMC9604469
OpenAlexW4306926009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.